Puri T
Senior Medical Advisor - Oncology, Eli Lilly and Company, Gurgaon, Haryana, India.
Indian J Cancer. 2017 Jan-Mar;54(1):83-88. doi: 10.4103/ijc.IJC_258_17.
Activating mutations in the epidermal growth factor receptor gene and rearrangement of the anaplastic lymphoma kinase gene exemplify the molecular characterization of nonsmall cell lung cancer (NSCLC), particularly adenocarcinoma, and its therapeutic relevance. Several genetic alterations with prognostic and predictive role, including ROS, RET, MET, KRAS, have now been identified in adenocarcinoma and some such as DDR2 and fibroblast growth factor receptor 1 in squamous cell carcinoma. This has heralded the development of agents targeted against these aberrations. Better knowledge of tumor biology and development of targeted agents has ushered an era of personalized treatment strategies in NSCLC, leading to improvements not only in tumor control and duration of life but also in quality of life.
表皮生长因子受体基因的激活突变和间变性淋巴瘤激酶基因的重排体现了非小细胞肺癌（NSCLC），尤其是腺癌的分子特征及其治疗意义。目前已在腺癌中鉴定出几种具有预后和预测作用的基因改变，包括ROS、RET、MET、KRAS，在鳞状细胞癌中也发现了一些如DDR2和成纤维细胞生长因子受体1等基因改变。这预示着针对这些异常的靶向药物的开发。对肿瘤生物学的深入了解和靶向药物的开发开启了NSCLC个性化治疗策略的时代，不仅改善了肿瘤控制和生存期，还提高了生活质量。
